CompletedNCT04425863

Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Eurnekian Public Hospital
Principal Investigator
Alfredo Secchi, M.D.
President Ethical Commitee, Hospital Eurnekian
Intervention
Ivermectin 5 MG/ML oral solution, Aspirin 250 mg tablets(drug)
Enrollment
167 enrolled
Eligibility
5 years · All sexes
Timeline
20202020

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04425863 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials